arXiv:2606. 11830v1 Announce Type: new Abstract: Background.
Machine-generated by The Flow from the publisher's headline and feed description — not written or checked by a human. The full article lives at arXiv AI.
LUCAID is an agentic multimodal AI system designed for precision lung cancer pathology, integrating nine modules that cover the entire routine workflow—from quality control and tumor detection to histological subtyping, microenvironment profiling, cellularity quantification, and biomarker scoring (PD‑L1, MET, TROP‑2). The system generates automated structured reports and allows interactive querying of module outputs. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert‑panel reference standard for clinically actionable decisions, outperforming five experienced thoracic pathologists who ranged from 68.3% to 81.1% concordance.
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological asses...
arXiv:2512. 01241v4 Announce Type: replace-cross Abstract: Large language models (LLMs) and medical AI tools are routinely used by physicians and patients for medical advice, yet their clinical safety profiles remain poorly characterized.
OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.
arXiv:2412. 17228v4 Announce Type: replace Abstract: Background: Clinical trials are essential to advancing cancer treatments, but fewer than 10% of adults with cancer enroll in therapeutic trials.
arXiv:2606. 03198v1 Announce Type: cross Abstract: Clinical AI evaluation increasingly delegates scoring to large language models (LLMs) acting as AI raters, yet their scoring behavior across evaluation conditions has not been quantitatively characterized.